Show simple item record

dc.contributor.authorBurchill, SA
dc.contributor.authorKinsey, SE
dc.contributor.authorPicton, S
dc.contributor.authorRoberts, P
dc.contributor.authorPinkerton, CR
dc.contributor.authorSelby, P
dc.contributor.authorLewis, IJ
dc.date.accessioned2018-09-17T15:18:51Z
dc.date.issued2001-01
dc.identifier1
dc.identifier.citationMEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 pp. 213 - 219
dc.identifier.issn0098-1532
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2755
dc.identifier.doi10.1002/1096-911X(20010101)36:1<213
dc.description.abstractBackground. Despite treatment with high-dose myeloblative chemotherapy and peripheral blood stem cell (PBSC) rescue, a high proportion of children with neuroblastoma relapse and die. Re-infusion of PBSC contaminated with tumour at the time of autologous transplantation may play a significant role in this relapse. In this study the frequency of tumour contamination in PB from children with neuroblastoma has been investigated. Procedure. Minimal residual disease was measured using RT-PCR for tyrosine hydroxylase (TH) mRNA in PBSCs from patients with advanced neuroblastoma. PBSCs from 18 patients in complete clinical remission were studied. Results. Studies in other cancers have suggested minimal contamination of PBSCs with tumour cells; TH mRNA was detected by RT-PCR in 50% (9/18) of PBSC harvests. Seventy-seven percent (7/9) of patients with TH mRNA in PBSC died of disease compared to 44% (4/9) who were TH mRNA-negative. Conclusions. Therefore, the presence of TH mRNA in PBSCs appeared to be associated with an unfavourable outcome, although this was not statistically significant. In summary, RT-PCR for TH mRNA is a sensitive method for the identification of tumour cells in PBSC harvest. The presence of TH mRNA in PBSC harvest may reflect disease status and be associated with an unfavourable outcome, although long-term clinical outcome studies in a larger patient cohort are required. Med. Pediatr. Oncol. 36:213-219, 2001. (C) 2001 Wiley-Liss, Inc.
dc.format.extent213 - 219
dc.languageeng
dc.language.isoeng
dc.titleMinimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma
dc.typeJournal Article
rioxxterms.versionofrecord10.1002/1096-911X(20010101)36:1<213
rioxxterms.licenseref.startdate2001-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfMEDICAL AND PEDIATRIC ONCOLOGY
pubs.notesAdvances in Neuroblastoma Research Meeting, BATH, ENGLAND, JUN 15-17, 1998 researcherid-numbers: pinkerton, ross/I-4808-2014 unique-id: ISI:000166167300052
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.volume36
pubs.embargo.termsNot known
dc.contributor.icrauthorPinkerton, Rossen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record